Organogenesis (ORGO) News Today $0.82 -0.08 (-9.02%) As of 02:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Organogenesis Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Organogenesis (NASDAQ:ORGO) Shares Down 3.6% - What's Next?October 23, 2026 | marketbeat.comOrganogenesis Holdings Inc. Announces Publication Of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit Of PuraPly®AM For Hard-To-Heal Diabetic Foot UlcersOctober 13, 2026 | marketscreener.comMOrganogenesis Holdings Inc. to Report Third Quarter 2026 Financial Results on November 5October 12, 2026 | quiverquant.comQOrganogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot UlcersOctober 12, 2026 | globenewswire.comOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026October 12, 2026 | globenewswire.comOrganogenesis (ORGO) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comOrganogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annuallyAugust 8, 2026 | seekingalpha.comOrganogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comOrganogenesis Launches New $75 Million At-The-Market OfferingAugust 6, 2026 | tipranks.comOrganogenesis Holdings Inc. Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | globenewswire.comOrganogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg UlcersJuly 27, 2026 | quiverquant.comQOrganogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg UlcersJuly 27, 2026 | globenewswire.comOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026July 9, 2026 | globenewswire.comOrganogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee OsteoarthritisJuly 6, 2026 | globenewswire.comOrganogenesis Stockholders Reelect Board and Approve Governance ItemsJune 16, 2026 | tipranks.comOrganogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster OverlookedJune 15, 2026 | seekingalpha.comOrganogenesis Earnings Call: Deep Pain, Long RoadJune 7, 2026 | theglobeandmail.comTruist Securities initiates coverage of Organogenesis Holdings (ORGO) with hold recommendationMay 29, 2026 | msn.comIs Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 UpdateMay 22, 2026 | finance.yahoo.comIs Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 UpdateMay 20, 2026 | insidermonkey.comOrganogenesis (ORGO) Q1 2026 Earnings TranscriptMay 8, 2026 | fool.comOrganogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comOrganogenesis Holdings Inc. Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comOrganogenesis Holdings Inc.: Organogenesis Completes Rolling Submission of Biologics License Application for ReNuMay 3, 2026 | finanznachrichten.deOrganogenesis Holdings Inc. Completes Biologics License Application Submission for ReNu® to Treat Knee OsteoarthritisApril 28, 2026 | quiverquant.comQOrganogenesis Completes Rolling Submission of Biologics License Application for ReNu®April 28, 2026 | globenewswire.comWhat's going on with Organogenesis stock on Wednesday?April 8, 2026 | msn.comWhat's Going On With Organogenesis Stock On Wednesday?April 8, 2026 | benzinga.comOrganogenesis Holdings, Inc. Class AApril 7, 2026 | edition.cnn.comOrganogenesis shares jump 20% following positive clinical trial resultsApril 7, 2026 | msn.comOrganogenesis stock rockets after diabetic foot ulcer trial posts statistically significant winApril 7, 2026 | msn.comOrganogenesis: Clinical Win De-Risks 2026, Recovery In SightApril 7, 2026 | seekingalpha.comORGO stock rallies after hours on clearing regulatory pathway for pain relief treatmentApril 7, 2026 | msn.comOrganogenesis stock surges 20% on trial resultsApril 7, 2026 | au.investing.comOrganogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMApril 6, 2026 | globenewswire.comOrganogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainApril 6, 2026 | globenewswire.comOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026April 6, 2026 | globenewswire.comOrganogenesis Advances NuShield Trial in Tough-to-Heal Leg Ulcers: What Investors Should WatchApril 3, 2026 | tipranks.comOrganogenesis Facing Hard Times As It Adjusts To CMS Rule ChangesMarch 27, 2026 | seekingalpha.comInsider Buying: Organogenesis (NASDAQ:ORGO) Director Buys 5,000 Shares of StockMarch 13, 2026 | insidertrades.comMichael Joseph Driscoll Buys 10,000 Shares of Organogenesis (NASDAQ:ORGO) StockMarch 12, 2026 | insidertrades.comOrganogenesis Director Makes Bold Insider Move With Fresh Share PurchaseMarch 11, 2026 | tipranks.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call TranscriptFebruary 28, 2026 | insidermonkey.comOrganogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call TranscriptFebruary 27, 2026 | seekingalpha.comOrganogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ...February 26, 2026 | finance.yahoo.comOrganogenesis (ORGO) Q4 2025 Earnings TranscriptFebruary 26, 2026 | fool.comOrganogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 EarningsFebruary 26, 2026 | quiverquant.comQOrganogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record RevenueFebruary 26, 2026 | globenewswire.comOrganogenesis Names Patrick McGuire Chief Accounting OfficerFebruary 23, 2026 | tipranks.comOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026February 19, 2026 | globenewswire.com Organogenesis Media Mentions By Week Organogenesis Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORGO News Sentiment▼0.820.69▲Average Healthcare News Sentiment Organogenesis News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORGO Articles This Week▼22▲ORGO Articles Average Week Organogenesis Trends on MarketBeatThis week vs. last weekNew Followers2+100%Searches2+100%Page Views1,599-16% Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Sensei Biotherapeutics News Entera Bio News Valneva News Aclaris Therapeutics News Neurogene News Monopar Therapeutics News Arvinas News REGENXBIO News Crescent Biopharma News Eupraxia Pharmaceuticals News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Organogenesis dated 10/23/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
